Respiratory syncytial virus: Concerns and control

Pediatrics in Review

Volumn 24, Issue 9, 2003, Pages 301-308

  McCarthy, Carol A ^a,b   Hall, Caroline Breese ^c  

^a Maine Medical Center   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; DORNASE ALFA; F PROTEIN VACCINE; G PROTEIN VACCINE; IMMUNOGLOBULIN; LIVE VACCINE; OXYGEN; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RETINOL; RIBAVIRIN; SURFACTANT; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; BRONCHODILATATION; CHILD; CLINICAL FEATURE; CYANOTIC HEART DISEASE; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DRUG SAFETY; ELDERLY CARE; FLUID THERAPY; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFANT DISEASE; INFECTION RISK; NEBULIZATION; OXYGEN THERAPY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; TREATMENT CONTRAINDICATION; VACCINATION; VACCINE PRODUCTION; VIRUS IDENTIFICATION; VIRUS INFECTION; VITAMIN SUPPLEMENTATION;

EID: 0041919701     PISSN: 01919601     EISSN: None     Source Type: Journal    
DOI: 10.1542/pir.24-9-301     Document Type: Review

References (0)